Analyst Barclays Initiates Coverage on C4 Therapeutics (CCCC) with Overweight Rating

Sep 17, 2025

Key Takeaways

Barclays initiates coverage on C4 Therapeutics (CCCC) with an ‘Overweight’ rating. Current price target set at $8.00 USD, marking a positi

CONNECT & FOLLOW